Cost-Effectiveness of Denosumab for Treating Bone Metastases from Solid Tumors: A Systematic Review (2017-2023).
- Author:
Cong WANG
1
;
Jin-Yu LIU
2
;
Min WAN
3
;
Qi YUAN
1
;
Yu ZHANG
1
;
Guang-Yi YU
4
,
5
;
Ru-Xu YOU
5
,
6
Author Information
- Publication Type:Systematic Review
- Keywords: bone metastases; cost‑effectiveness; denosumab; systematic review; zoledronic acid
- MeSH: Denosumab/therapeutic use*; Humans; Bone Neoplasms/economics*; Cost-Benefit Analysis
- From: Chinese Medical Sciences Journal 2025;40(3):219-231
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:This systematic review examines recent pharmacoeconomic literature on denosumab' cost-effectiveness for bone metastasis treatment, providing evidence-based insights to guide healthcare policy decisions.
METHODS:A comprehensive literature search was performed across Cochrane, PubMed, EMBASE (Ovid), CNKI, and Wanfang databases to identify original articles published between 2017 and 2023. Key words consisted of bone metastases, denosumab, and cost-effectiveness in the search strategy. The methodological quality of the included studies was assessed utilizing the revised Consolidated Health Economic Evaluation Reporting Standards (CHEERS 2022). Data was extracted regarding methodological characteristics and cost-effectiveness analyses.
RESULTS:A total of 111 studies were retrieved, of which 6 met the inclusion criteria. All included studies were based on clinical trials and published literature data and exhibited high methodological quality. Up to 83% (5 out of 6) of comparisons demonstrated that denosumab was more cost-effective or dominant compared to zoledronic acid. The adjusted incremental cost-effectiveness ratios varied substantially by tumor type, ranging from CZK 436,339.09 to USD 136,234 per skeletal-related event avoided and from CZK 61,580.95 to USD 118,392.11 per quality-adjusted life year gained.
CONCLUSIONS:The majority of the included studies support denosumab as a more cost-effective treatment option for bone metastases in solid tumors compared to zoledronic acid. The application of CHEER (2022) enhances the reliability of pharmacoeconomic evaluations.
